Published in BMC Infect Dis on September 16, 2017
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol (2014) 4.82
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol (2013) 2.87
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology (2005) 1.91
Natural history of hepatitis C. J Hepatol (2014) 1.73
Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol (2003) 1.63
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study. J Hepatol (2013) 1.54
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther (2010) 1.51
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (2014) 1.46
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat (2002) 1.22
Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion (2009) 1.21
Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat (2011) 1.18
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology (2015) 1.17
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology (2016) 1.17
The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther (2014) 1.14
Cellular immune response to hepatitis C virus (HCV) in nonviremic blood donors with indeterminate anti-HCV reactivity. Transfusion (2009) 1.13
Natural history of chronic hepatitis C virus infection. Dig Liver Dis (2007) 1.13
Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making (2004) 1.05
Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat (2002) 1.03
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol (2014) 1.00
Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat (2004) 0.94
The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion (2012) 0.85
Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat (2011) 0.84
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol (2014) 0.81
Why do I treat my patients with mild hepatitis C? Liver Int (2016) 0.81
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat (2016) 0.80
Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepat (2004) 0.79
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol (2014) 0.79
[Hepatitis C in Northern Norway--an 8-year material]. Tidsskr Nor Laegeforen (2002) 0.76
Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J Viral Hepat (2016) 0.76
Enhanced surveillance of hepatitis C in the EU, 2006 - 2012. J Viral Hepat (2014) 0.76
Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol (2010) 0.76
Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007-2012. J Clin Virol (2017) 0.76
Cure prevents more than transmission of hepatitis C virus. Hepatology (2016) 0.75